RAJAF Cordyceps Sunshine Biotech Holdings Co., Ltd.
Fundamentals / CIK 0001885680 / USDCordyceps Sunshine Biotech Holdings Co., Ltd. reported $1.25M in revenue and a net loss of $155K for the fiscal year ended December 31, 2025 (down 0.6% year over year), with a 61.1% gross margin and a -11.3% operating margin.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open RAJAF in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025$1.25M -0.6% YoY
-
Operating Income FY 2025-$141K -11.3% margin
-
Net Income FY 2025-$155K -12.4% net margin
-
Diluted EPS FY 2025$0.00 Split-adjusted
-
Free Cash Flow FY 2025-- Operating CF less CapEx
-
Cash & ST Investments Dec 31, 2025$3.2K Total debt: $13K
Annual revenue and net income
5 fiscal years (2021 to 2025), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Revenue | $1.25M | $1.25M | $883K | $53K | $879K |
| Cost of Revenue | $485K | $347K | $116K | $14K | $1.06M |
| Gross Profit | $761K | $906K | $766K | $40K | -$176K |
| Research & Development | -- | -- | -- | $118K | $25K |
| Selling, General & Admin | -- | -- | -- | $576K | $301K |
| Total Operating Expenses | $902K | $1.09M | $539K | $455K | $119K |
| Operating Income | -$141K | -$184K | $228K | -$415K | -$119K |
| EBITDA | $68K | $240K | $285K | -$391K | $30K |
| Interest Income | -- | -- | $7 | $10 | $7 |
| Interest Expense | -- | -- | $27K | $72K | $12K |
| Income Before Tax | -$155K | -$191K | $191K | -$415K | -$119K |
| Income Tax Expense | -- | $35K | $22K | $792 | $351 |
| Net Income | -$155K | -$226K | $752K | -$720K | -$491K |
| Basic EPS | $0.00 | $0.00 | $0.01 | -$0.01 | $0.00 |
| Diluted EPS | $0.00 | $0.00 | $0.01 | -$0.01 | $0.00 |
| Basic Shares Outstanding | 111.1M | 111.1M | 111.1M | 104.4M | 100.0K |
| Diluted Shares Outstanding | 111.1M | 111.1M | 111.1M | 104.4M | 100.0K |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $3.2K | $37K | $23K | $6.6K | $100K | $294 |
| Cash & Short-Term Investments | $3.2K | $37K | $23K | $6.6K | $100K | $294 |
| Accounts Receivable, Net | -- | $305 | -- | $150K | $358K | -- |
| Inventory | $674K | -- | -- | $314K | $480K | $685K |
| Other Current Assets | $100K | $58K | $2.4K | -- | -- | -- |
| Total Current Assets | $998K | $602K | $327K | $502K | $1.13M | $949K |
| Property, Plant & Equipment, Net | $3.63M | $3.91M | $2.81M | $76K | $1.71M | $1.71M |
| Other Non-Current Assets | $14K | $13K | $14K | -- | -- | -- |
| Total Non-Current Assets | $3.66M | $4.02M | $3.02M | $1.60M | $2.13M | $1.88M |
| Total Assets | $4.66M | $4.62M | $3.35M | $2.10M | $3.26M | $2.83M |
| Accounts Payable | $365K | $276K | $185K | $751K | $112K | $123 |
| Short-Term Debt | -- | -- | -- | $57K | -- | -- |
| Other Current Liabilities | $7.9K | $5.2K | -- | $1.38M | -- | -- |
| Total Current Liabilities | $5.19M | $4.99M | $2.97M | $2.52M | $2.92M | $2.41M |
| Long-Term Debt | -- | -- | $431K | $414K | -- | -- |
| Total Non-Current Liabilities | $0 | $13K | $537K | $535K | $617K | $425K |
| Total Liabilities | $5.19M | $5.00M | $3.50M | $3.06M | $3.54M | $2.84M |
| Total Debt (incl. Leases) | $13K | $100K | $628K | $649K | $270K | $16K |
| Common Stock | $11K | $11K | $11K | $11K | $10K | $10K |
| Retained Earnings | -$854K | -$699K | -$473K | -$1.22M | -$504K | -$13K |
| Accumulated Other Comp. Income | $87K | $91K | $89K | $41K | -$3.7K | $664 |
| Total Stockholders' Equity | -$535K | -$376K | -$152K | -$951K | -$276K | -$13K |
| Total Equity | -$535K | -$376K | -$152K | -$951K | -$276K | -$13K |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $3.2K | $37K | $23K | $6.6K | $100K | $294 |
| Cash & Short-Term Investments | $3.2K | $37K | $23K | $6.6K | $100K | $294 |
| Accounts Receivable, Net | -- | $305 | -- | $150K | $358K | -- |
| Inventory | $674K | -- | -- | $314K | $480K | $685K |
| Other Current Assets | $100K | $58K | $2.4K | -- | -- | -- |
| Total Current Assets | $998K | $602K | $327K | $502K | $1.13M | $949K |
| Property, Plant & Equipment, Net | $3.63M | $3.91M | $2.81M | $76K | $1.71M | $1.71M |
| Other Non-Current Assets | $14K | $13K | $14K | -- | -- | -- |
| Total Non-Current Assets | $3.66M | $4.02M | $3.02M | $1.60M | $2.13M | $1.88M |
| Total Assets | $4.66M | $4.62M | $3.35M | $2.10M | $3.26M | $2.83M |
| Accounts Payable | $365K | $276K | $185K | $751K | $112K | $123 |
| Short-Term Debt | -- | -- | -- | $57K | -- | -- |
| Other Current Liabilities | $7.9K | $5.2K | -- | $1.38M | -- | -- |
| Total Current Liabilities | $5.19M | $4.99M | $2.97M | $2.52M | $2.92M | $2.41M |
| Long-Term Debt | -- | -- | $431K | $414K | -- | -- |
| Total Non-Current Liabilities | $0 | $13K | $537K | $535K | $617K | $425K |
| Total Liabilities | $5.19M | $5.00M | $3.50M | $3.06M | $3.54M | $2.84M |
| Total Debt (incl. Leases) | $13K | $100K | $628K | $649K | $270K | $16K |
| Common Stock | $11K | $11K | $11K | $11K | $10K | $10K |
| Retained Earnings | -$854K | -$699K | -$473K | -$1.22M | -$504K | -$13K |
| Accumulated Other Comp. Income | $87K | $91K | $89K | $41K | -$3.7K | $664 |
| Total Stockholders' Equity | -$535K | -$376K | -$152K | -$951K | -$276K | -$13K |
| Total Equity | -$535K | -$376K | -$152K | -$951K | -$276K | -$13K |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Net Income | -$155K | -$226K | $752K | -$720K | -$491K |
| Depreciation & Amortization | $209K | $424K | $57K | $24K | $149K |
| Change in Receivables | -- | -- | -- | $186K | -$354K |
| Change in Inventory | -$359K | -- | -$193K | $49K | -$167K |
| Change in Payables | $77K | $105K | $183K | -$122K | $106K |
| Operating Cash Flow | -$36K | $312K | $360K | -$321K | -$365K |
| Capital Expenditure | -- | -$349K | -$319K | -$475 | -$100K |
| Free Cash Flow | -- | -$37K | $40K | -$322K | -$465K |
| Investing Cash Flow | -- | -$306K | -$320K | -$475 | -$111K |
| Common Stock Issued | -- | -- | -- | -- | $232K |
| Financing Cash Flow | -- | -- | -$32K | $246K | $575K |
| Net Change in Cash | -$34K | $14K | $7.0K | -$84K | $99K |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Gross Margin | 61.1% | 72.3% | 86.8% | 74.2% | -20.0% |
| Operating Margin | -11.3% | -14.7% | 25.8% | -778.8% | -13.6% |
| Net Profit Margin | -12.4% | -18.1% | 85.2% | -1350.9% | -55.8% |
| Return on Assets (ROA) | -3.3% | -4.9% | 22.4% | -34.2% | -15.0% |
| Current Ratio | 0.19x | 0.12x | 0.11x | 0.20x | 0.39x |
| Quick Ratio | 0.06x | 0.01x | 0.01x | 0.07x | 0.22x |
| Revenue Growth (YoY) | -0.6% | +42.0% | +1555.7% | -93.9% | -- |
| Gross Profit Growth (YoY) | -16.1% | +18.3% | +1837.4% | -- | -- |
| Operating Income Growth (YoY) | -- | -180.7% | -- | -- | -- |
| Net Income Growth (YoY) | -- | -130.1% | -- | -- | -- |
| EPS Growth (YoY) | -- | -100.0% | -- | -- | -- |
| Operating Cash Flow Growth (YoY) | -111.5% | -13.3% | -- | -- | -- |
| Free Cash Flow Growth (YoY) | -- | -192.5% | -- | -- | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.